FDA approvals: Lipfendra leads 7 actions (2026)

Coverage and the lead story

The public FDA record for the July 10, 2026, 5:00 p.m. ET to July 17, 2026, 5:00 p.m. ET window shows four substantive human-drug actions, one label-only drug supplement, and two medical-device decisions. The lead event is Merck's Lipfendra, the first FDA-approved oral PCSK9 inhibitor: it brings an injection-free option into a large cholesterol market, but its commercial test will be whether payers and patients value the convenience enough to move beyond statins and established injectables.

The July 10 Keytruda/Padcev muscle-invasive bladder-cancer expansion was covered in the prior issue and is not counted again here. On the device side, the two decisions below are both dated July 10 in the public CDRH records; no later PMA or 510(k) decision was visible in the FDA records available for this issue's cutoff. That is a narrower signal than a company press-release roundup, because companies sometimes announce a clearance days or weeks after the FDA decision record.

At a glance

Lipfendra (enlicitide), Merck Sharp & Dohme: First oral PCSK9 inhibitor; 56% and 59% placebo-adjusted LDL-C reductions at Week 24 in two Phase 3 populations.
Revtorpyk (gedatolisib), Celcuity: Pan-PI3K/mTOR therapy for PIK3CA-wild-type HR-positive/HER2-negative advanced breast cancer; VIKTORIA-1 produced a large progression-free-survival advantage over fulvestrant alone.
Retevmo (selpercatinib), Eli Lilly: Traditional approval for RET fusion-positive solid tumors in adults and children age 2 and older, converting earlier accelerated approvals.
Leqembi IQLIK (lecanemab-irmb), Eisai/Biogen: Once-weekly subcutaneous initiation, including at-home dosing, for early Alzheimer's disease; launch is planned for late August.
Hextend HMW Hydroxyethyl Starch (6%), Hospira/Pfizer: A label supplement removing the pregnancy category from the product labeling, not a new indication.
Devices: New York Embroidery Studio's NYES Tuff Cuff L3 Disposable Gowns received 510(k) clearance; Medtronic's EverFlex peripheral-stent PMA supplement approved a manufacturing-process change.

Lipfendra makes PCSK9 inhibition a pill

On July 16, the FDA approved Lipfendra (enlicitide) tablets for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH), as an adjunct to diet and exercise. The sponsor is Merck Sharp & Dohme LLC. The 20-mg tablet is taken once daily, received Priority Review, and is the first oral drug approved to block PCSK9, a protein that limits the liver's ability to clear LDL cholesterol from the bloodstream. 1

The approval rests on two randomized, double-blind, placebo-controlled Phase 3 trials enrolling 3,207 adults who still needed LDL-C reduction despite maximally tolerated statin therapy. In the trial enrolling adults with established atherosclerotic cardiovascular disease or elevated risk, Lipfendra lowered LDL-C by 56% versus placebo at Week 24. In the HeFH trial, the reduction was 59% versus placebo. The first trial's adverse-reaction profile was similar to placebo; in the HeFH study, diarrhea and dizziness were more common with Lipfendra. A cardiovascular-outcomes trial is still running, so the approval establishes LDL lowering, not yet a demonstrated reduction in heart attacks or strokes. 2

The addressable pool is large but should not be confused with the number of likely prescriptions. The CDC says about 86 million U.S. adults age 20 or older have total cholesterol above 200 mg/dL, while treatment decisions depend on LDL-C, cardiovascular risk, prior therapy, tolerability, and coverage. Lipfendra enters a field that already includes statins, ezetimibe, and injectable PCSK9-pathway drugs. BioSpace reported a $315 monthly launch price, below the roughly $500-$600 monthly range it cited for injectable PCSK9 competitors, and reported an RBC Capital Markets estimate of approximately $5 billion in peak sales by 2034. Those are market estimates, not Merck guidance. 3 4

Commercial read: The pill removes an important friction point, but reimbursement will decide whether it becomes a broad add-on to statins or remains a specialty option for patients who need additional LDL-C lowering. For clinicians, the immediate distinction is convenience; for investors, the next disclosures to watch are formulary placement, early prescription volume, and whether the outcomes study converts biochemical efficacy into cardiovascular-outcomes confidence.

Revtorpyk targets a broad breast-cancer biomarker group

The FDA approved Revtorpyk (gedatolisib) on July 14 for adults with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer without a detected PIK3CA mutation after progression on or after at least one line of endocrine therapy in the metastatic setting. It is used with fulvestrant, with or without palbociclib. Celcuity is the sponsor. The drug inhibits all four class I PI3K isoforms and both mTORC1 and mTORC2, a broader pathway hit than agents aimed at a single node. The review used Real-Time Oncology Review and the Assessment Aid. 5

The decision was based on Study 1 of the Phase 3 VIKTORIA-1 trial, which enrolled 392 adults. In the triplet arm, Revtorpyk plus palbociclib and fulvestrant produced a median progression-free survival of 9.3 months versus 2.0 months with fulvestrant alone, a hazard ratio of 0.24. The doublet produced median progression-free survival of 7.4 months versus 2.0 months, with a hazard ratio of 0.33. Objective response rates were 32% for the triplet, 28% for the doublet, and 1% for fulvestrant alone. The label warns about stomatitis, severe rash, hyperglycemia, and embryo-fetal toxicity; stomatitis occurred in 72% of patients receiving the triplet and 58% receiving the doublet in the FDA-reviewed data. 6

Celcuity's own framing makes the potential population unusually broad for a biomarker-defined launch: HR-positive/HER2-negative disease accounts for about 70% of breast cancers, and the company estimates roughly 60% of that subtype is PIK3CA wild-type. The approved population is still narrower because it requires advanced disease and prior endocrine therapy. Celcuity expects a late-Q3 commercial launch, has created an expanded-access program, and plans a supplemental application for the PIK3CA-mutated population in Q3 2026. 6

Commercial read: Revtorpyk has the potential to compete for a large post-endocrine-treatment population, but the regimen is not simple and the safety-monitoring burden is real. The first market signal was skeptical: Reuters reported that Celcuity shares fell nearly 19% on July 15 as a delayed commercial launch and label concerns overshadowed the approval. The signal is useful because it separates regulatory success from launch execution; investors are already pricing in questions about timing, tolerability, and the breadth of the label. 7

Retevmo converts a tumor-agnostic accelerated approval

On July 14, the FDA granted traditional approval to Retevmo (selpercatinib) for adults and children age 2 and older with locally advanced or metastatic solid tumors harboring a RET gene fusion. The fusion must be confirmed by an FDA-approved test, and the disease must have progressed after prior systemic treatment or lack a satisfactory alternative. Eli Lilly is the sponsor. The action converts earlier accelerated approvals granted for adults in 2022 and pediatric patients in 2024. 8

The supporting evidence came from the LIBRETTO-001 multicenter, open-label, multi-cohort trial. Among 75 patients with RET fusion-positive tumors other than non-small-cell lung cancer or thyroid cancer, the objective response rate was 47%, and the median duration of response was 24.5 months. The responding tumor types included colorectal, pancreatic, salivary-gland, soft-tissue sarcoma, bile-duct, skin, breast, ovarian, small-intestinal, and neuroendocrine cancers. The FDA label carries warnings and precautions covering hepatotoxicity, interstitial lung disease or pneumonitis, hypertension, QT prolongation, bleeding, hypersensitivity, tumor lysis syndrome, impaired wound healing, hypothyroidism, and embryo-fetal toxicity. 8

Commercial read: This is a regulatory de-risking event for an existing Lilly product, not a new mechanism entering the market. The eligible population is biomarker-selected and therefore smaller than the broad solid-tumor wording suggests, but traditional approval strengthens the durability of the indication and supports continued testing across rare RET fusion-positive tumors. For clinicians, the operational requirement is reliable molecular testing; for patients, the value is a treatment option that spans tumor types rather than a new organ-specific label.

Leqembi IQLIK moves initiation out of the infusion center

The FDA page for this action is dated July 13, while Eisai and Biogen's approval release is dated July 14. The substance is clear: FDA approved a supplemental BLA for once-weekly subcutaneous Leqembi IQLIK (lecanemab-irmb) as an initiation dose for adults with early Alzheimer's disease, meaning mild cognitive impairment or mild dementia due to Alzheimer's disease. Eisai and Biogen share commercialization, with Eisai leading development and regulatory submissions. 9 10

The approved initiation regimen is 500 mg once weekly as two 250-mg injections, each delivered by autoinjector in about 15 seconds. After 18 months of IV or subcutaneous treatment, patients may use 360 mg subcutaneously once weekly for maintenance. The approval allows patients to start and continue treatment at home through a specialty pharmacy, and Eisai says the U.S. launch is planned for late August 2026.

The evidence package did not come from a separate large outcomes trial of the autoinjector. It combines the established clinical benefit of IV lecanemab with pharmacokinetic and biomarker evidence that weekly subcutaneous dosing provides equivalent exposure and similar amyloid removal. The safety profile is generally similar to IV administration, with localized injection reactions added to the familiar risks of anti-amyloid treatment. ARIA, including brain edema and microhemorrhage, can be serious or fatal; the labeling recommends a baseline brain MRI and periodic monitoring, and recommends ApoE epsilon-4 testing before treatment to inform ARIA risk. 10

Commercial read: The approval changes the site of care more than it changes the drug's biology. It can reduce infusion-chair use, travel, and administration time, but it does not remove the need for amyloid confirmation, MRI surveillance, risk counseling, or careful patient selection. The late-August launch date also means the near-term investor question is execution: specialty-pharmacy distribution, payer handling of the new formulation, and whether home administration expands the treated population or mainly shifts existing patients away from infusion centers.

A label-only drug action: Hextend

FDA's July 14 approval letter for Hextend HMW Hydroxyethyl Starch (6%) was a supplemental, Changes Being Effected action that removed the pregnancy category from the product labeling. It did not add a new indication or create a new patient population. The letter is addressed to Hospira, Inc., a Pfizer company. 11

For readers tracking commercial impact, this is a compliance and labeling action rather than a launch catalyst. It belongs in a complete regulatory log, but it should not be compared with Lipfendra, Revtorpyk, Retevmo, or Leqembi IQLIK as a new therapeutic entry.

Device decisions: one new surgical gown clearance and one manufacturing supplement

NYES Tuff Cuff L3 Disposable Gowns

FDA cleared 510(k) K261949 on July 10 for NYES Tuff Cuff L3 Disposable Gowns, submitted by New York Embroidery Studio. The FDA record classifies it as a surgical gown under product code FYA and records a substantially equivalent decision. The record does not provide a patient-facing indication; the relevant users are operating-room staff, and the patient benefit is indirect through sterile-barrier protection. 12

Commercial read: This is a routine consumables clearance, not a new diagnostic or therapeutic platform. The opportunity is tied to hospital procurement, contract manufacturing, and supply reliability rather than a measurable change in clinical practice. Because the public record does not provide a market-size estimate or product-specific clinical study, stronger commercial claims would be speculation.

EverFlex self-expanding peripheral stent system

FDA approved PMA supplement P110023S068 on July 10 for Medtronic Vascular's EverFlex Self-expanding Peripheral Stent System. The action was a 30-day notice for a process change involving the manufacturer, sterilizer, packager, or supplier; the record describes changes to a fixture used with a Branson ultrasonic welder and related manifold inspection. It did not add an indication or change the target patient population for the peripheral stent. 13

Commercial read: The value is manufacturing continuity and quality-system execution. For investors and hospital buyers, the important question is whether the change improves throughput or resilience without creating a supply interruption; it is not a new market-expansion event.

What matters next

This week's actions divide into four different kinds of regulatory value. Lipfendra opens a new route of administration in a high-prevalence disease, so payer access and adherence will matter as much as LDL-C efficacy. Revtorpyk has a broad biomarker-defined opportunity, but its launch timing and tolerability will determine whether the VIKTORIA-1 signal becomes routine practice. Retevmo's traditional approval reduces uncertainty around an established tumor-agnostic asset. Leqembi IQLIK is a site-of-care innovation whose success depends on home-use logistics and safety monitoring, not just on the convenience of an autoinjector.

For clinicians, the practical checklist is label-specific: monitor glucose and oral toxicity with Revtorpyk, confirm RET fusions before Retevmo, and preserve MRI and ARIA safeguards with Leqembi. For patient advocates, the access questions are formulary coverage for Lipfendra, expanded-access timing for Revtorpyk, specialty-pharmacy availability for Leqembi IQLIK, and whether home administration actually lowers the burden of care. For investors, the next evidence will be commercial: Lipfendra uptake, Celcuity's late-Q3 launch, and whether Leqembi IQLIK changes treatment capacity rather than simply changing the delivery setting.

FDA approvals: Lipfendra leads 7 actions